Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
With
UCB Japan Co. Ltd.
This study was initiated by Otsuka Pharmaceutical Co., Ltd and transferred to Astellas on 12/04/2012.
Age
20–74
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who participated in Study 275-08-001 and meet all of the criteria described below.
* Patients who did not reach ACR20, and prematurely discontinued Study 275-08-001 at Week 16 or completed Study 275-08-001 by Week 24.
* Patients who are able to receive treatment with MTX, by Week 52.
You may not be if
Patients who experienced an important protocol deviation as mentioned below during Study 275-08-001.
Patients who received live or attenuated vaccines during Study 275-08-001(Except for influenza or pneumococcal vaccines).
Patients who were found to have tuberculosis on a chest X-ray during Study 275-08-001.
Patients who required treatment for the same infection at two or more different times during Study 275-08-001
Women who are pregnant, are lactating, of childbearing potential and wish to conceive during the study and post-study 3 months.
Patients whom the investigator has decided to be inappropriate for participation in the study
Clareo Health | Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
